A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Trial details
- Registry ID
- NCT05608044
- Drugs studied
- Balstilimab, Botensilimab, Standard of Care
TrialRedline tracks 5 clinical trials sponsored by Agenus Inc.: 5 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerNCT05608044 | Balstilimab, Botensilimab, Standard of Care | Active not recruiting | 2027-09Estimated |
| A Study of Botensilimab in Participants With Metastatic Pancreatic CancerNCT05630183 | Botensilimab, Gemcitabine, Nab-paclitaxel | Completed | 2026-01-05Actual |
| A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaNCT00081809 | autologous human tumor-derived HSPPC-96 | Completed | 2005-06Actual |
| A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaNCT05529316 | Balstilimab, Botensilimab | Terminated | 2026-04-27Actual |
| RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerNCT03894215 | AGEN1884, AGEN2034 | Terminated | 2025-03-26Actual |
Names as written in the registry records.
NCT05529316 · Agenus Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Objective Response Rate Description: Objective response rate will be determined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Time frame: First dose through up to 3 months. After: Measure: Objective Response Rate Description: Objective response rate will be determined using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Time frame: Up to 40 months.
Before: Estimated. After: Actual.
Before: Feb 2028. After: 27 Apr 2026.
Before: Active not recruiting. After: Terminated.
NCT05630183 · Agenus Inc.
Before: Estimated. After: Actual.
Before: 5 Dec 2025. After: 5 Jan 2026.
Before: Active not recruiting. After: Completed.
Before: Estimated. After: Actual.
Before: 212 participants (planned). After: 211 participants (actual).
Before: Estimated. After: Actual.
Before: Aug 2025. After: 26 Mar 2025.
Before: Active not recruiting. After: Terminated.
NCT05529316 · Agenus Inc.
Before: 174 participants (actual). After: 150 participants (actual).